Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage pharmaceutical company whose news flow centers on the development of next-generation pain and central nervous system therapeutics that incorporate built-in abuse and overdose protection. Company updates frequently highlight progress across its proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) platforms, which are designed to create tamper-resistant prodrugs and overdose-protected medications.
Investors and healthcare observers following ENSC news can expect regular coverage of clinical milestones for PF614, the company’s TAAP™ extended-release oxycodone analogue for moderate to severe pain, including pivotal Phase 3 trial activities and regulatory interactions with the U.S. Food and Drug Administration. News items also describe the evolution of PF614-MPAR, which combines PF614 with MPAR® overdose protection and is advancing under FDA Breakthrough Therapy designation with support from multi-year NIDA grants.
Beyond pain management, Ensysce news includes developments in its ADHD pipeline, such as patent notices for PF8026, an immediate-release amphetamine prodrug that uses TAAP™ and MPAR® technologies to address stimulant abuse and overdose risk. Updates on PF9001, the company’s lead opioid use disorder candidate supported by a HEAL grant, also appear in the company’s communications.
Additional ENSC news covers intellectual property achievements extending MPAR® patent protection, federal grant awards, symposium presentations at major pain conferences, and financing transactions such as preferred stock offerings and registered direct offerings disclosed via SEC filings and press releases. This news page aggregates these announcements so readers can track Ensysce’s clinical, regulatory, intellectual property, and capital markets developments in one place.
Ensysce Biosciences (NASDAQ:ENSC) has released two video segments from its symposium at the International Association for the Study of Pain (IASP) 2024 World Congress in Amsterdam. The symposium focused on opioid use worldwide and Ensysce's innovative opioid drug products for severe pain relief. Dr. William Schmidt, CMO, explained the government support received from NIH and FDA, and highlighted how PF614, Ensysce's lead agent, aligns with ideal pain product characteristics. CEO Dr. Lynn Kirkpatrick emphasized the company's novel approach using TAAP and MPAR platforms to develop opioids with reduced abuse and overdose potential. Ensysce plans to begin a Phase 3 pivotal trial soon and explore PF614's use in cancer treatment, aiming to provide prescribers with new options for effective patient care.
Ensysce Biosciences (NASDAQ:ENSC) has announced a $5 million concurrent registered direct offering and exercise of warrants. The company will issue and sell 3,553,194 shares of common stock at $0.47 per share. Additionally, certain outstanding warrants to purchase 7,203,504 shares will be exercised at a reduced price of $0.47 per share. In a private placement, Ensysce will issue unregistered Series A-3 and A-4 warrants to purchase up to 14,358,450 shares each. The offerings are expected to close around August 29, 2024. H.C. Wainwright & Co. is the exclusive placement agent. Ensysce plans to use the proceeds for developing its TAAP and MPAR programs and for working capital, supplementing a recent $14 million NIH grant for PF614-MPAR development.
Ensysce Biosciences (NASDAQ:ENSC) has received IRB approval for the PF614-MPAR-102 protocol, marking a significant milestone in the clinical development of their FDA-designated Breakthrough Therapy for severe pain relief. This study, supported by a $14 million federal grant, will evaluate the pharmacokinetics of oxycodone and PF614 when co-administered with nafamostat. PF614-MPAR is unique as the only opioid with both abuse and overdose protection to receive Breakthrough Therapy designation. The company plans to initiate the three-part trial immediately, with first data expected in mid-2025. This development brings Ensysce closer to introducing a new generation of safer pain management products.
Ensysce Biosciences (NASDAQ:ENSC) has received a $14 million multi-year grant from the NIH and National Institute on Drug Abuse (NIDA) for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection. This follows the FDA's Breakthrough Therapy designation for PF614-MPAR in January 2024. The funding will support the completion of the Phase 1b clinical trial, PF614-MPAR-102, over approximately three years.
PF614-MPAR is designed to provide optimal pain relief at prescribed doses while limiting accidental or intentional overdose. This grant brings the total federal funding awarded to Ensysce to $40 million, supporting their mission to develop innovative solutions for severe pain relief with reduced potential for opioid abuse and overdose.
Ensysce Biosciences (NASDAQ:ENSC) reported Q2 2024 financial results and provided updates on its opioid programs. Key highlights include:
- PF614-MPAR advancing to Phase 1b study
- PF9001 selected as lead candidate for Opioid Use Disorder program
- PF614 Phase 3 protocol being finalized for FDA submission
- Q2 cash position of $1.0 million
- Q2 net loss of $2.0 million, down from $2.2 million in Q2 2023
- R&D expenses decreased to $0.9 million from $1.6 million year-over-year
The company is progressing its TAAP™ and MPAR® technologies to develop safer opioid analgesics with abuse deterrent and overdose protection features.
Ensysce Biosciences (NASDAQ:ENSC) hosted a successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress in Amsterdam. The symposium, titled 'Severe Pain: A New Chapter for Safer Analgesics', focused on innovative solutions for severe pain relief while reducing opioid abuse and overdose risks. Key discussions included:
1. Current landscape of severe pain treatment
2. new therapeutic agents in the past decade
3. Pros and cons of opioid use and genetic influences on pain
4. Ensysce's Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) technologies
5. Safety and effectiveness of PF614 and PF614-MPAR
6. Upcoming clinical studies and commercial positioning
The symposium received positive feedback on its content and Ensysce's clinical strategy.
Ensysce Biosciences (NASDAQ:ENSC) provides a mid-year 2024 update on its clinical-stage pharmaceutical developments for severe pain relief with reduced opioid abuse and overdose potential. Key highlights include:
1. PF614: Completed End of Phase 2 FDA meeting, published bioequivalence study results, and established manufacturing partnerships.
2. PF614-MPAR: Received FDA Breakthrough Therapy designation, applied for $15 million NIH/NIDA grant, and advanced to second clinical trial.
3. Opioid Use Disorder (OUD) program: Selected lead drug candidate PF9001, a TAAP methadone analogue with potentially lower cardiovascular side effects.
The company is finalizing the PF614 Phase 3 protocol and anticipates initiating enrollment later in 2024. Ensysce continues to seek non-dilutive federal funding to support its innovative pain relief solutions.
Ensysce Biosciences (NASDAQ:ENSC) announced it will host a symposium at the IASP 2024 World Congress on Pain on August 8, 2024, in Amsterdam. The symposium titled 'Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen and Dr. William Schmidt, who will discuss the landscape of severe pain treatment, trends in treatment, and the safety and effectiveness of Ensysce's PF614 and PF614-MPAR based on clinical data. CEO Dr. Lynn Kirkpatrick emphasized the importance of the event for presenting their technology platforms, TAAP and MPAR, which aim to reduce prescription drug abuse and overdose.
Ensysce Biosciences, a clinical-stage pharmaceutical company (NASDAQ: ENSC), shared key insights from the 2024 EPHMRA Annual Meeting, held in London on June 25-26. Geoff Birkett, Chief Commercial Officer, participated in discussions about the future of healthcare research and emphasized the importance of new technologies in addressing pain and opioid abuse. Ensysce's TAAP™ and MPAR® platforms were highlighted as examples of innovative solutions. Birkett also led a session on integrating AI and human intelligence in drug development, underscoring the need for active involvement from company staff and prescribers. He expressed optimism about the potential of advanced technologies to improve patient lives and stressed the ongoing importance of research in drug development. Additionally, the meeting reinforced the significance of combining AI with human insights.
Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company, announced a partnership with manufacturing expert Purisys to scale the production of its lead opioid use disorder (OUD) drug candidate, PF9001. Developed using Ensysce's TAAP technology, PF9001 aims to reduce the cardiovascular side effects commonly associated with methadone. This collaboration aims to expedite the drug's progression to IND studies. Ensysce is also advancing its pain treatment candidate, PF614, towards Phase 3 trials. CEO Dr. Lynn Kirkpatrick highlighted Purisys' expertise in controlled substance chemistry and its role in improving the manufacturing processes for PF614.